Abstract
We report results of a conservative treatment for brain metastases from malignant melanoma with a combination of irradiation and chemotherapy (fotemustine and/or DTIC). To date, 12 patients have been treated. There was a complete remission of the brain metastases in four patients. In two patients a partial remission was observed. The mean survival of the responder was 8.2 months (95% confidence interval 3.8–12.6 months). The most common side effects were thrombocytopenia, leukopenia, and alopecia. Altogether, the treatment was well tolerated. As the outcome of patients with brain metastases from malignant melanoma is generally poor, this combined chemo- and radiation therapy may provide improved care for such patients.
Similar content being viewed by others
References
Stevens G, Firth I, Coates A: Cerebral metastases from malignant melanoma Radiother Oncol 23: 185–191, 1992
Atkinson L: Melanoma of the central nervous system. Aust N Z J Surg 48: 14–16, 1978
Schadendorf D, Worm M, Czarnetzki B: Brain metastases of metastatic malignant melanoma: Response to DTIC and interferon-gamma. J Neuro Oncol 16: 77–79, 1993
Phuphanich S, Jacobs M, Spiers A: Response of recurrent brain metastases in malignant melanoma to 5-fluorouracil and interferon-± therapy. J Neuroimag 4: 114–116, 1994
Madajewicz S, West CR, Park HC, Ghoorah J, Avellanosa AM, Takita H, Karakousis C, Vincent R, Caracandas J, Jennings E: Phase II Study – Intra-arterial BCNU therapy for metastatic brain tumors. Cancer 47: 653–657, 1981
Avril MF, Bonneterre J, Cupissol D, Grob JJ, Kalis B, Fumoleau P, Kerbrat P, Israel L, Fargeot P, Lambert D: Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 28A: 1807–1811, 1992
Binder M, Winkler A, Dorffner R, Glebowski E, Wolff K, Pehamberger H: Fotemustine plus dacarbazine in advanced stage III malignant melanoma. Eur J Cancer 28A: 1814–1816, 1992
Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer JJ, Bonneterre J, Kerbat P, Bonerandi JJ, Bugat R, Montcuquet P, Cupissol D, Lauvin R, Vilmer C, Prache C, Bizzari JP: (1990) Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66: 1873–1878, 1990
Khayat D, Avril MF, Gerad B, Bertrand P, Bizzari JP, Cour V: Fotemustine: an overview of its clinical activity in dissminated malignant melanoma. Melanoma Res 2: 147–151, 1992
Merimsky O, Inbar M, Gerad B, Chaitchik S: Fotemustine – an advance in the treatment of metastatic melanoma. Melanoma Res 2: 401–406, 1992
Schallreuter KU, Wenzel E, Brassow FW, Becker J, Breitbart EW, Teichmann W: Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chem Pharm 29: 85–87, 1991
Kleeberg UR, Engel E, Israels P, Br¨ocker EB, Tilgen W, Kennes C, Gerard B, Lejeune F, Glabbeke MV, Lentz MA: Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTCMelanoma Cooperative Group (MCG). Melanoma Res 5: 195–200, 1995
Brega K, Robinson WA, Winston K, Wittenberg W: Surgical treatment of brain metastases in malignant melanoma. Cancer 66: 2105–2110, 1990
Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS: Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Cancer 45: 679–683, 1980
Fedorscsak I, Sipos L, Horvath A, Kontra G, Bognar L, Osztie E: Multiple intracranial melanoma metastases treated with surgery and radiosurgery with long term control. J Neuro Oncol 16: 173–176, 1993
Lejeune FY, Lienard D, Sales F, Badr-El-Din H: Surgical management of distant melanoma metastases. Sem Surg Oncol 8: 381–391, 1992
Somaza S, Kondziolka D, Lunsford LD, Kirkwood JM, Flickinger JC: Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 79: 661–666, 1993
Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM: Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 53: 2550–2552, 1984
Retsas S, Gershuny AR: Central nervous system involvment in malignant melanoma. Cancer 61: 1926–1934, 1988
Ulrich J, Gademann G, Rosin C, Kühne KH, Gollnick H: Simultaneous chemotherapy and radiotherapy for cerebral metastases from malignant melanoma. Melanoma Res 7 Suppl 1: S 18 Abstracts
Bröcker EB, Bohndorf W, Kämpgen E, Trcka J, Messer P, Tilgen W, Engenhart K, Flentje M: Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res 6: 399–401, 1996
HidalgoV, Dy C, Hidalgo OF, Calvo F: Simultaneous Radiotherapy and cis-Platinum for the treatment of brain metastases. Am J Clin Oncol 10: 205–209, 1987
Willner J, Bohndorf W: ZNS-Metastasen beim maligner Melanom. Strahlenther Onkol 171: 165–173, 1995
Buckner J: Surgery, radiation therapy, and chemotherapy for metastatic tumors to the brain. Curr Opin Oncol 4: 518–524, 1992
Engenhart R, Kimmig BN, Höver KH, Wowra B, Romahn J, Lorenz WJ, van Kaick G, Wannenmacher M: Long Term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation. Cancer 71: 1353–1361, 1993
Adler JR, Cox RS, Kaplan I, Martin DP: Stereotactic radiosurgical treatment of brain metastases. J Neurosurg 76: 444–449, 1992
Merimsky O, Reider-Grosswasser M, Inbar M, Kovner F, Chaitchik S: Cerebral metastatic melanoma: correlation between clinical and CT findings. Melanoma Res 2: 385–391, 1992
Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ulrich, J., Gademann, G. & Gollnick, H. Management of Cerebral Metastases from Malignant Melanoma: Results of a Combined, Simultaneous Treatment with Fotemustine and Irradiation. J Neurooncol 43, 173–178 (1999). https://doi.org/10.1023/A:1006280304912
Issue Date:
DOI: https://doi.org/10.1023/A:1006280304912